HEALTH● LOWJul 2 · Jul 2, 2026, 6:20 PM
Novartis gene therapy Itvisma approved in EU for spinal muscular atrophy
Seeking Alpha Tech
Novartis's gene therapy, Itvisma, has received approval in the European Union for the treatment of spinal muscular atrophy. This marks a significant development in available treatments for the condition.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH17m agoKerala State Drugs Control dept. seeks curbs on inter-State drug procurement to ensure traceabilityThe HinduHEALTH33m ago93% of children affected by diphtheria outbreaks not fully vaccinated – OfficialPremium TimesHEALTH36m agoDr. Sandra G. Martín, dentist: "Health always comes before a pretty tooth. First biology and then aesthetics. The important thing is that everything is healthy."ClarínHEALTH1h agoMore workers are skipping doctor's visits over money worriesCBS News